Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156728 | 0.89 | MAPT (0.52) | MEN1KMT2AALDH1A1MAPTMTNR1A | |
| SCHEMBL7644874 | 0.87 | CASR (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13632217 | 0.85 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27795134 | 0.82 | CYP19A1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2156996 | 0.82 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2156481 | 0.81 | PLA2G2A (0.42) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL26473 | 0.80 | MTNR1B (0.67) | KMT2ASMN1; SMN2MAPTCYP19A1MTNR1A | |
| SCHEMBL27513948 | 0.77 | CASR (0.47) | — | |
| SCHEMBL2156932 | 0.77 | CCR2 (0.53) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8502661 | 0.76 | MTNR1A (0.53) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999000360-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| EP-0887342-A2 | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1998-12-30 | — | — | EP | claimed |
| EP-1950200-B1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | LILLY CO ELI (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1202963-B1 | SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1220839-B1 | HYDROXYFUNCTIONAL AMIDE 1H-INDOLE DERIVATIVES ACTIVE AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1100492-B1 | INDOLE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7026348-B2 | Indole sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1058547-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | SHIONOGI & CO (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-6939890-B2 | Antiinflammatory agents; sepsis shock; rheumatic disorders | ELI LILLY AND COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999000360-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0887342-A2 | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998047507-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998042343-A1 | METHOD FOR TREATMENT OF CHRONIC BRONCHITIS | ELI LILLY AND COMPANY (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |